New York State Common Retirement Fund Acquires 378,340 Shares of Cryoport, Inc. (NASDAQ:CYRX)

New York State Common Retirement Fund increased its holdings in Cryoport, Inc. (NASDAQ:CYRX) by 29.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,642,752 shares of the company’s stock after purchasing an additional 378,340 shares during the quarter. New York State Common Retirement Fund owned approximately 3.36% of Cryoport worth $25,446,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of CYRX. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Cryoport by 13.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,462 shares of the company’s stock worth $157,000 after acquiring an additional 1,395 shares during the period. WINTON GROUP Ltd purchased a new position in shares of Cryoport during the 3rd quarter worth approximately $163,000. Pathstone Family Office LLC purchased a new position in shares of Cryoport during the 3rd quarter worth approximately $165,000. Quantbot Technologies LP grew its holdings in shares of Cryoport by 109.0% during the 3rd quarter. Quantbot Technologies LP now owns 12,838 shares of the company’s stock worth $176,000 after acquiring an additional 6,694 shares during the period. Finally, Arizona State Retirement System grew its holdings in shares of Cryoport by 5.4% during the 4th quarter. Arizona State Retirement System now owns 13,665 shares of the company’s stock worth $212,000 after acquiring an additional 696 shares during the period. 92.90% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

CYRX has been the topic of a number of research analyst reports. UBS Group upped their target price on Cryoport from $14.50 to $17.00 and gave the stock a “neutral” rating in a report on Friday, March 15th. Needham & Company LLC reduced their target price on Cryoport from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, March 13th. Jefferies Financial Group assumed coverage on Cryoport in a research report on Thursday, April 4th. They issued a “buy” rating and a $21.00 price target on the stock. Finally, Stephens reissued an “equal weight” rating and issued a $17.00 price target on shares of Cryoport in a research report on Wednesday, March 13th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $18.63.

Cryoport Stock Performance

CYRX stock opened at $16.38 on Friday. The stock has a market capitalization of $805.24 million, a PE ratio of -7.45 and a beta of 1.60. Cryoport, Inc. has a 12-month low of $9.00 and a 12-month high of $24.17. The company has a current ratio of 11.73, a quick ratio of 11.16 and a debt-to-equity ratio of 0.82. The stock’s 50 day simple moving average is $16.86 and its 200 day simple moving average is $14.93.

Cryoport (NASDAQ:CYRX) last released its quarterly earnings data on Tuesday, March 12th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.19). The business had revenue of $57.26 million during the quarter, compared to the consensus estimate of $58.27 million. Cryoport had a negative net margin of 42.69% and a negative return on equity of 11.86%. As a group, research analysts forecast that Cryoport, Inc. will post -1.31 earnings per share for the current fiscal year.

Insider Activity at Cryoport

In related news, Director Ramkumar Mandalam sold 3,217 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $14.68, for a total value of $47,225.56. Following the transaction, the director now directly owns 43,187 shares of the company’s stock, valued at approximately $633,985.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Ramkumar Mandalam sold 3,217 shares of the stock in a transaction on Friday, March 15th. The stock was sold at an average price of $14.68, for a total transaction of $47,225.56. Following the transaction, the director now directly owns 43,187 shares of the company’s stock, valued at approximately $633,985.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Jerrell Shelton sold 3,723 shares of the stock in a transaction on Monday, March 11th. The shares were sold at an average price of $16.35, for a total value of $60,871.05. Following the transaction, the chief executive officer now directly owns 636,951 shares in the company, valued at $10,414,148.85. The disclosure for this sale can be found here. In the last three months, insiders have sold 73,940 shares of company stock valued at $1,147,538. 10.10% of the stock is owned by corporate insiders.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.